Who are Retin-A's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sohonos, TRIFAROTENE, Panretin, Targretin, Soriatane, Differin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tretinoin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Retin-A — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Retin-A (TRETINOIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Retinoid [EPC]. Area: Oncology.

marketed Retinoid [EPC] Nuclear receptor ROR-beta Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Retin-A (TRETINOIN) — Bausch Health. Tretinoin works by binding to and activating nuclear receptors, which helps to regulate cell growth and differentiation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Retin-A TARGET	TRETINOIN	Bausch Health	marketed	Retinoid [EPC]	Nuclear receptor ROR-beta	1971-01-01
Sohonos	PALOVAROTENE	Ipsen	marketed	Retinoid [EPC]	Retinoic acid receptor gamma	2023-01-01
TRIFAROTENE	TRIFAROTENE		marketed	Retinoid [EPC]		2019-01-01
Panretin	ALITRETINOIN	Advanz	marketed	Retinoid [EPC]	Retinoic acid receptor beta	1999-01-01
Targretin	BEXAROTENE	Bausch Health	marketed	Retinoid [EPC]	Retinoic acid receptor RXR-beta	1999-01-01
Soriatane	ACITRETIN	Stiefel Labs Inc	marketed	Retinoid [EPC]	Bile salt export pump	1996-01-01
Differin	ADAPALENE	Galderma Labs Lp	marketed	Retinoid [EPC]	Retinoic acid receptor beta	1996-01-01

Recent regulatory actions (last 90 days)

2026-03-25 — Retin-A · FDA · approved · US · Bausch Health

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-09-15 — Differin · 8435502 · Formulation · US
2026-09-15 — Differin · 8709392 · Formulation · US
2028-05-31 — Differin · 7998467 · Formulation · US
2038-08-22 — Retin-A · 10653656 · Formulation · US
2038-08-22 — Retin-A · 11324710 · Method of Use · US

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Retin-A — Competitive Intelligence Brief. https://druglandscape.com/ci/tretinoin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing